Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...

Art Still is one of the best defensive ends in University of Kentucky football history, becoming the No. 2 overall pick in ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis An exploratory ...